A phase IV, single-centre, single-blinded, randomized controlled trial to assess safety and immunogenicity of VSVΔG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults.

Project Details

Short titleA phase IV, single-centre, single-blinded, randomized controlled trial to assess safety and immunogenicity of VSVΔG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults.
StatusActive
Effective start/end date1/11/24 → 30/11/25

Funding

  • Merck Sharp & Dohme